Drugs With Tirzepatide Linked to Nonarteritic Anterior Ischemic Optic Neuropathy (NAION)
In a rush? You can use our Quick Contact Form to tell us the basic information about your case.
This Zepbound and Mounjaro Eye Side Effect NAION Information Page provides some important evidence regarding an increased risk of non-arteritic ischemic optic neuropathy, or NAION, associated with these two tirzepatide-containing drugs.
The FDA has been investigating “potential signals” of the eye side effect NAION with Mounjaro and Zepbound — the active ingredient is tirzepatide for both medications — as well as other glucagon-like peptide-1 (GLP-1) receptor agonist drugs, collectively referred to as GLP-1 RAs. To learn more about how Zepbound and Mounjaro might be associated with the eye side effect NAION, you can read our June 2025 Drug Injury Watch blog post, “Current FDA Safety Investigation: NAION With Mounjaro, Zepbound, and Other GLP-1 RAs”.
An August 2025 JAMA Network Open article, “Semaglutide or Tirzepatide and Optic Nerve and Visual Pathway Disorders in Type 2 Diabetes“, provided more evidence for an increased risk of non-arteritic ischemic optic neuropathy, or NAION, with Ozempic (semaglutide) or Mounjaro (tirzepatide) in diabetes patients.
Here are some of the facts presented in that August 2025 medical article regarding the Mounjaro eye side effect NAION, specifically in diabetes patients:
- Nonarteritic anterior ischemic optic neuropathy (NAION) is characterized by loss of vision due to decreased blood flow to the optic nerve.
- The medical researchers compared Mounjaro (tirzepatide) with other antidiabetic medications for the associated risk of NAION in patients with type 2 diabetes who had no prior diagnosis of any eye disorder.
- Mounjaro (tirzepatide) is a newer and more potent GLP-RA to treat type 2 diabetes and obesity.
- In a population of patients with type 2 diabetes who had no prior diagnosis of eye diseases, this cohort study found that when Mounjaro (tirzepatide) was compared with other antidiabetic medications, there was an increased risk of NAION.
Besides Mounjaro, as we stated earlier, there is a second GLP-1RA drug that contains the active ingredient tirzepatide, Zepbound. That medication is used for obesity and weight loss purposes. There is some evidence that the NAION eye side effect may be associated with Zepbound, given that both drugs have the active ingredient tirzepatide.
Of course, we will continue to monitor relevant medical journals for additional studies concerning the association of NAION with Mounjaro and Zepbound. Further, we await the outcome of that FDA investigation into the eye side effect NAION with Mounjaro and Zepbound.
Free Case Evaluation for Zepbound or Mounjaro Eye Side Effect NAION
We encourage you to submit a Zepbound / Mounjaro Eye Side Effect NAION Case Evaluation Form online – it is free, confidential, and there is no obligation. Or, if you prefer, call 910-256-2971 to speak directly to attorney Tom Lamb about a possible Zepbound or Mounjaro drug injury lawsuit. Either way, you will get Mr. Lamb’s impressions – not an intake person, a paralegal, or some other lawyer – about your case based on his over 20 years of experience handling drug injury cases.
Most Recent Articles About Zepbound and Mounjaro Eye Side Effect NAION With Vision Loss
Increased Risk NAION Label Change: Ozempic, Zepbound, Etc. | FDA 2026
What you need to know: An increased risk NAION label change ordered by the FDA in November applies to Ozempic, Wegovy, Rybelsus, Zepbound, Mounjaro, and other medications in GLP-1 RA drug class.
The Prescribing Information documents, or drug labels, for all glucagon-like peptide-1 receptor agonists (GLP-1 RAs) will add information about the potential increased risk of non-arteritic anterior ischemic optic neuropathy (NAION) pursuant to an FDA-issued Drug Safety Communication on November 9, 2026. This increased-risk NAION label change applies to Ozempic, Zepbound, and other medications in the GLP-1 RA class of drugs.
To read more of this article, click below:
From that November 2026 FDA document, “FDA Requires Safety Labeling Changes for Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RAs) Due to Potential Increased Risk of Rare But Serious Eye Condition“, regarding the significance of this increased risk NAION label change:
Patients and caregivers should be aware of a potential increased risk of NAION, a rare condition that can result in acute, painless, decreased vision in one eye, including permanent vision loss, with GLP-1 RA use.
Symptoms of NAION include sudden, painless vision loss in one eye that patients may notice upon waking; blurred or missing portions of vision (visual defects such as blind spots or tunnel vision); distortion of colors; and reduced central sharpness (e.g., blurry or hazy spots). Patients should contact their health care professional right away if they have any of these symptoms.
If a patient has had a NAION event, they should talk with their health care professional about whether to continue taking their GLP-1 RA medication or to stop it.
Before and after this increased risk NAION label change, we are investigating possible drug injury lawsuits for people diagnosed with NAION while using Ozempic, Wegovy, or Rybelsus — all of which are semaglutide-containing drugs — as well as people who were using Zepbound or Mounjaro — both of which are tirzepatide-containing drugs.
Coincidentally, our last Drug Injury Watch article on this NAION side-effect drug safety issue was published on October 16, 2026: “Vision Loss Associated With Ozempic, Mounjaro, And Other GLP-1 Drugs – People With Vision Loss Want Warnings Even If Risk Of NAION Eye Injury Is Low“.
For people diagnosed with NAION while using Ozempic, Wegovy, or Rybelsus, as well as people diagnosed with NAION while using Zepbound or Mounjaro, we provide possible drug injury lawsuit evaluations that are free, confidential, and without any obligation (that is, no strings attached):
Ozempic / Wegovy / Rybelsus Vision Loss Case Evaluation Form
Zepbound / Mounjaro Eye Side Effect NAION Case Evaluation Form
Two other ways to get an evaluation of a possible NAION drug injury lawsuit are to email lawyer Tom Lamb at TJL@LambLawOffice.com or call our office at 910-256-2971.
Of course, we are looking to see the legal ramifications of this increased risk NAION label change ordered by the FDA in November 2026 for those drug injury lawsuits already filed for people diagnosed with NAION while using Ozempic, Wegovy, or Rybelsus, as well as Zepbound or Mounjaro.
And to be clear, we remain interested in investigating new cases for people diagnosed with NAION while using Ozempic, Zepbound, etc. after this November 2026 increased risk NAION label change.
Earlier articles about eye-related side effects of Mounjaro and Zepbound:
- NAION With Ozempic, Wegovy, Mounjaro, or Zepbound Use: Why Are There Still No Warnings?
- Mounjaro, Ozempic Vision Loss Lawsuits Filings Increase – 2026 News Reports
- NAION Cases Filed in Courts for Vision Loss Legal Compensation
- NAION Linked To Zepbound, Mounjaro, Ozempic, Wegovy: 2026 News Update
- Mounjaro and Ozempic NAION Vision Loss Lawsuits: Federal Court MDL No. 3163
- Ozempic and Mounjaro Increased Risk of NAION More Than Other Diabetes Drugs
- NAION With Tirzepatide-containing Drugs Mounjaro and Zepbound